On June 12, 2020, Iovance Biotherapeutics, Inc. announced Michael C. Swartzburg, the company’s Vice President, Finance, was appointed to replace Mr. Timothy Morris as the company’s Principal Accounting Officer, Effective as of June 10, 2020,. Mr. Swartzburg has served as the company’s Vice President, Finance since March 2018. From June 2014 to August 2016, Mr. Swartzburg served in roles at Adverum Biotechnolgies, Inc., including serving as Vice President, Finance, Controller, and Principal Accounting Officer.